Islet Sciences Inc Share Price

Equities

Delayed OTC Markets Other stock markets 14:53:58 26/07/2017 BST			5-day change	1st Jan Change
0.0127 ^USD	+5.75%		+5.75%	-76.93%

Duration

Period

Style

Islet Sciences, Inc. Publishes Data Supporting Remogliflozin Etabonate as a Potential Treatment for NAFLD and NASH	04/05/15	GL
Islet Sciences, Inc. Presented at 50th International Liver Conference	23/04/15	GL
Islet Sciences, Inc. COO to Present at Metabolic Leaders Forum	24/03/15	GL
Islet Sciences, Inc. COO to Present at EASL: Remogliflozin Etabonate as Novel Treatment for Non-alcoholic Steatohepatitis (NASH)	09/03/15	GL
Islet Sciences, Inc. Confirms Issuance of U.S. Patent for Using SGLT2 Inhibitors to Treat NASH/NAFLD	05/03/15	GL

1 day

+5.75%

Sector

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.68%	42.75B
LONZA GROUP AG	+47.70%	41.61B
MODERNA, INC.	+11.95%	41.34B
CELLTRION, INC.	-8.83%	26.59B
ICON PUBLIC LIMITED COMPANY	+6.34%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-23.26%	18.12B
MEDPACE HOLDINGS, INC.	+30.33%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.34%	11.76B
UNITED THERAPEUTICS CORPORATION	+8.43%	11B